A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with R/R B-Cell Malignancies.

Trial Identifier: D9960C00001
Sponsor: AstraZeneca
Start Date: September 2024
Primary Completion Date: February 2028
Study Completion Date: February 2028
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Melbourne, AU, 3000
AU Nedlands, AU, 6009
CA, Alberta Calgary, Alberta, CA, T2N 5G2
CA, ON Toronto, ON, CA, M5G 2M9
CA, QC Montreal, QC, CA, H3T 1R2
CN Hangzhou, CN, 310003
CN Shanghai, CN, 200025
DE München, DE, 81675
DE Ulm, DE, 89081
DE Würzburg, DE, 97080
DK København Ø, DK, 2100
ES Barcelona, ES, 08035
ES L'Hospitalet de Llobregat, ES, 08908
ES Madrid, ES, 28040
FR Pessac, FR, 33604
FR Villejuif Cedex, FR, 94805
IT Bologna, IT, 40138
IT Milano, IT, 20133
JP Chuo-ku, JP, 104-0045
JP Kashiwa, JP, 277-8577
US, CA La Jolla, CA, US, 92093
US, NC Charlotte, NC, US, 28203
US, NC Winston Salem, NC, US, 27157
US, NJ Hackensack, NJ, US, 07601
US, NY New York, NY, US, 10029
US, NY New York, NY, US, 10021
US, Texas Houston, Texas, US, 77030
US, WA Seattle, WA, US, 98109